Replies to post #582523 on NorthWest Biotherapeutics Inc (NWBO)

[SkyLimit2022]

It sounds like Tim Olivier would prefer a placebo trial—he’s in luck!

There’s a great placebo trial at UCLA today supported by the U.S. NIH and Merck. The interim survival data are quite astonishing.

https://clinicaltrials.gov/ct2/show/NCT04201873

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=171254048&txt2find=Lab%20rats






https://www.uclahealth.org/news/brain-cancer-discovery-clinical-trials

[flipper44]

This poor misguided author, Dr. Olivier, does not appear to understand crossover confoundment (randomization confoundment as a direct consequence), immunotherapeutic delayed impact, pseudoprogression, unprecedented long term survival and the ethics of denying crossover, and defers to Temodar as the gold standard when it typically achieves only 3% five year survival.

He does use googly eyes on Twitter to draw attention to his journal article. Perhaps he missed his calling.

[Bright Boy]

Amazing how the French will never get over the English snub !!! And articles like that are living proof of the embarrassing reasons why!!!

Cheers,

BB

[beachhyena]

This is just another hit piece. How many co authors are on this one. That will tell the story. What a joke.

[Lykiri]

Denis Migliorini@MiglioriniDenis
Neuro Oncologist, Brain tumor Immunologist, passion about immune cell engineering
March 19

Join us for the upcoming French Society of Neurology conference in Paris. The line up is impressive!
Extremely honored to present updates on our research alongside pioneers in neuro oncology and neurosurgery with Roger Stupp, Hugues Duffau, Martin Van den Bent among others

Oncology Division - Geneva University Hospital@DOncologie
Oct.4, 2022

Join us for Prof. Roger Stupp's Lecture tomorrow! Pr Stupp is a pioneer in innovative drug development for brain tumors, 2 FDA approved therapies are based on his research for #Glioblastoma. He will be hosted by Pr Migliorini Denis

https://twitter.com/DOncologie/status/1537316021639471104/photo/1
Martin van den Bent@MartinvdenBent

Critical review of the report on the DCvax-L trial: the trial did not meet its prospectively defined endpoint and post-hoc analyses with poorly selected external controls do not replace a proper prospective trial

Critical review of the report on the DCvax-L trial: the trial did not meet its prospectively defined endpoint and post-hoc analyses with poorly selected external controls do not replace a proper prospective trial https://t.co/3kJnHYW4P6

— Martin van den Bent (@MartinvdenBent) December 23, 2022

[Lykiri]

Autologous tumor lysate-loaded dendritic cell vaccination in glioblastoma: What happened to the evidence?
Authors: T. Olivier , D. Migliorini

https://www.sciencedirect.com/science/article/pii/S0035378723009190
Denis Migliorini@MiglioriniDenis
Neuro Oncologist, Brain tumor Immunologist, passion about immune cell engineering
March 19

Join us for the upcoming French Society of Neurology conference in Paris. The line up is impressive!
Extremely honored to present updates on our research alongside pioneers in neuro oncology and neurosurgery with Roger Stupp, Hugues Duffau, Martin Van den Bent among others

Oncology Division - Geneva University Hospital@DOncologie
Oct.4, 2022

Join us for Prof. Roger Stupp's Lecture tomorrow! Pr Stupp is a pioneer in innovative drug development for brain tumors, 2 FDA approved therapies are based on his research for #Glioblastoma. He will be hosted by Pr Migliorini Denis

https://twitter.com/DOncologie/status/1537316021639471104/photo/1

Check out the latest @Cancer_Cell Voices revisiting the current state of vaccine development for cancer. Among other experts Piere Yves Dietrich and Pr. Denis Migliorini discuss promise and challenges for brain tumors.

Martin van den Bent@MartinvdenBent

Critical review of the report on the DCvax-L trial: the trial did not meet its prospectively defined endpoint and post-hoc analyses with poorly selected external controls do not replace a proper prospective trial

Critical review of the report on the DCvax-L trial: the trial did not meet its prospectively defined endpoint and post-hoc analyses with poorly selected external controls do not replace a proper prospective trial https://t.co/3kJnHYW4P6

— Martin van den Bent (@MartinvdenBent) December 23, 2022

[dstock07734]

Olivier is not even an expert on GBM. He is such a lightweight in academia. Just look his publications. Pretty soon he will find out this paper only brings stigma to his reputation instead of the fame he is looking for.

https://scholar.google.com/citations?hl=en&user=6FBeQT4AAAAJ

[Dr Bala]

I read only the conclusions section, which revealed that these pathetic authors don't even know the ABCs of this trial. No point in paying attention to this unlearned article.

[ilovetech]

Lykiri - Let's put it this way, "I lost a lot of respect for so called medical experts, especially in recent years." We have non-doctors on this board who run circles around these schmucks." Sad, but true.

ILT

[pgsd]

Timothée Olivier, MD has written a number of papers questioning DCVax results.

"due to the described DCVax-L trial weaknesses, we cannot draw any conclusions on potential efficacy"

Blake gave a good response to his posting:-

https://t.co/q8sm3ax4yp pic.twitter.com/pEz7aBVVv0

— Blake (@MC17595091) April 3, 2023

[dennisdave]

Just for a few here to get your priorities straight

https://www.sciencedirect.com/science/article/pii/S0035378723009190

Now, THIS is a real short attack, not yes or no if NWBO's website is up to date and if its relevant.